Pharmaceuticals, Biotechnology and Life Sciences
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in…
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV –…
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm…
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing…
– Appointed Dr. Roger Sidhu as Chief Medical Officer – – Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating…
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused…
– Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class…
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5…
Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in…
Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis(3)…